Results 11 to 20 of about 14,945 (175)

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis

Frontiers in Pediatrics, 2022
ObjectiveMacrophage activation syndrome (MAS) is a life-threatening, potentially fatal condition associated with systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) is a key cytokine in the pathogenesis of sJIA MAS.
Mikhail M. Kostik, Eugenia A. Isupova, Konstantin Belozerov, Tatyana S. Likhacheva, Evgeny N. Suspitsin, Evgeny N. Suspitsin, Evgeny N. Suspitsin, Rinat Raupov, Vera V. Masalova, Irina A. Chikova, Margarita F. Dubko, Olga V. Kalashnikova, Vyacheslav G. Chasnyk, Randy Q. Cron   +13 more
doaj   +1 more source

Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy

Scientific Reports, 2021
Canakinumab is a fully human monoclonal antibody that specifically neutralizes human interleukin (IL)-1β and has been approved by the US Food and Drug Administration for treating different types of autoinflammatory disorders such as cryopyrin-associated ...
Wen-Wei Lin, Yun-Chi Lu, Bo-Cheng Huang, Chih-Hung Chuang, Yi-An Cheng, I.-Ju Chen, Hui-Ju Liu, Kai-Wen Ho, Tzu-Yi Liao, En-Shuo Liu, Ting-Yi Wu, Long-Sen Chang, Shih-Ting Hong, Tian-Lu Cheng   +13 more
doaj   +1 more source

Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases

The Turkish Journal of Pediatrics, 2020
Background and Objectives. The aim of this observational retrospective cohort study was to demonstrate indications and response rates of the patients with pediatric rheumatic diseases that used canakinumab. Method. The files of the patients
Mustafa Çakan, Şerife Gül Karadağ, Nuray Aktay Ayaz   +2 more
doaj   +1 more source

Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

International Journal of Infectious Diseases, 2021
Objectives: Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia.
Daniele Generali, Giancarlo Bosio, Fabio Malberti, Antonio Cuzzoli, Sophie Testa, Laura Romanini, Antonio Fioravanti, Alessandro Morandini, Luca Pianta, Guglielmo Giannotti, Erika Maria Viola, Matteo Giorgi-Pierfranceschi, Marina Foramitti, Rosa Angela Tira, Ilaria Zangrandi, Giulia Chiodelli, Andrea Machiavelli, Maria Rosa Cappelletti, Alessia Giossi, Valeria De Giuli, Chiara Costanzi, Chiara Campana, Ottavia Bernocchi, Marianna Sirico, Alessia Zoncada, Alfredo Molteni, Sergio Venturini, Fabiola Giudici, Maurizio Scaltriti, Angelo Pan   +29 more
doaj   +1 more source

Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial

EClinicalMedicine, 2022
Summary: Background: Patients with type 2 diabetes and obesity have chronic activation of the innate immune system possibly contributing to the higher risk of hyperinflammatory response to SARS-CoV2 and severe COVID-19 observed in this population.
Matthias Hepprich, Jonathan M. Mudry, Claudia Gregoriano, Francois R. Jornayvaz, Sebastian Carballo, Anne Wojtusciszyn, Pierre-Alexandre Bart, Jean-Daniel Chiche, Stefan Fischli, Thomas Baumgartner, Claudia Cavelti-Weder, Dominique L. Braun, Huldrych F. Günthard, Felix Beuschlein, Anna Conen, Emily West, Egon Isenring, Stefan Zechmann, Gabriela Bucklar, Yoann Aubry, Ludovic Dey, Beat Müller, Patrick Hunziker, Philipp Schütz, Marco Cattaneo, Marc Y. Donath   +25 more
doaj   +1 more source

Association between C-reactive protein with all-cause mortality in ELSA-Brasil cohort [PDF]

, 2020
Background: High-sensitive C-reactive protein (hsCRP) has been proposed as a marker of incident cardiovascular disease and vascular mortality, and it may also be a marker of non-vascular mortality.
Alvim Matos, Sheila M., Azevedo, Douglas R. M., Barreto, Sandhi M., Cappuccio, Francesco P., Giatti Gonçalves, Luana, Griep, Rosane H., Ji, Chen, Maluf, Chams B., Miller, Michelle A., Ribeiro, Luiz P., Vidigal, Pedro G.   +10 more
core   +3 more sources

Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events

CJC Open, 2022
Background: Cardiovascular (CV) disease is a condition with high levels of morbidity and mortality. Canakinumab is a novel monoclonal antibody therapy that has been shown to reduce CV events but is associated with side effects and high cost.
Kevin E. Boczar, MD, Rob Beanlands, MD, George Wells, PhD, Doug Coyle, PhD   +3 more
doaj   +1 more source

Canakinumab [PDF]

mAbs, 2010
Canakinumab (ACZ885, Ilaris) is a human anti-IL-1beta monoclonal antibody developed by Novartis. Its mode of action is based on the neutralization of IL-1beta signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009 the drug was approved by the US Food and Drug Administration for the treatment of
openaire   +2 more sources

Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease [PDF]

, 2018
Adult-onset Still's disease (AOSD) is a rare inflammatory disease of unknown etiology typically characterized by episodes of spiking fever, evanescent rash, arthralgia, leukocytosis, and hyperferritinemia. The pivotal role of interleukin (IL)-1 and other
Baggio, Chiara, Bindoli, S, Galozzi, P, Oliviero, F, Sfriso, P   +4 more
core   +1 more source

Gouty arthritis of the spine in a renal transplant patient : a clinical case report: an unusual presentation of a common disease [PDF]

, 2015
Axial gout is a well-documented but uncommon manifestation of gout. Its mimicking nature and the impracticality of axial joint aspiration might considerably delay its diagnosis.
Dhaese, Sofie, STRYCKERS, MARIJKE, Terryn, Wim, VAN DER MEERSCH, HANS, Van Laecke, Steven   +4 more
core   +1 more source